• News
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Presentations
    • The Share
      • Largest Shareholders
      • Share Capital Development
      • Rights Issue / Företrädesemission 2020
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
logo
  • News
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Management
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Press Releases
      • English
      • Swedish
    • Presentations
    • The Share
      • Largest Shareholders
      • Share Capital Development
      • Rights Issue / Företrädesemission 2020
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Contact
Home / Investors
  • Overview
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • The Share
    • Share Monitor
    • Largest Shareholders
    • Share Capital Development
    • Rights Issue / Företrädesemission 2020
    • Previous Share Issuances
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Nomination Committee / Valberedning
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact

Investor Relations

Welcome to Alzinova AB’s IR pages.

Alzinova AB is a company specializing in the treatment of Alzheimer’s disease – one of our major health scourges, without effective treatment options.

Latest press releases

  • 2021-02-25 | Regulatory Alzinova AB Year-end Report 2020
  • 2021-01-08 | Regulatory Drug substance for the ALZ-101 vaccine is now produced – meets the requirements of the upcoming clinical Phase 1b study
View all

Latest news

  • 2021-04-09 Podcast - Alzheimer's Vaccine & Early-Stage Projects
  • 2021-03-19 Webcast with CEOs of Swedish Alzheimer's companies
View all

Latest financial reports

  • Alzinova Bokslutskommuniké 2020
  • Alzinova Year end report 2020
View all
  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin